About

James M. Daly has served as an ACADIA director since January 2016. He was Executive Vice President and Chief Commercial Officer at Incyte Corporation (2012-2015), earlier held multiple leadership roles at Amgen, and spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline. He currently serves on the boards of argenx SE, Cytokinetics and Madrigal Pharmaceuticals. He earned a B.S. in pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.

Roles

Acadia Pharmaceuticals Inc.
Director · Current role
January 2016–present
Incyte Corporation
Executive Vice President and Chief Commercial Officer
October 2012 - June 2015
Amgen, Inc.
Senior Vice President, North America Commercial Operations
2002 - 2012
Glaxo Wellcome / GlaxoSmithKline
Senior Vice President, General Manager (16+ years)

External Roles

argenx SE
Director
Cytokinetics, Incorporated
Director
Madrigal Pharmaceuticals, Inc.
Director

Director Compensation

FY 2025
Fees earned or paid in cash
$36,846
ComponentAnnual Board and committee cash retainers earned in FY2025
Option awards
$176,392
ComponentAnnual stock option grant, ASC 718 grant-date fair value
Stock awards
$180,705
ComponentAnnual restricted stock unit grant, ASC 718 grant-date fair value
Total
$393,942

Also at Acadia Pharmaceuticals Inc.

Related

See how VectorShift works for your firm

Request Demo